title: Sidelining safety--the FDA's inadequate response to the IOM.
authors.affiliation: Center on Drugs and Public Policy, Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, USA.
authors.forename: Sheila Weiss
authors.initials: SW
authors.lastname: Smith
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions; D033161:Government Regulation; D017146:Models, Organizational; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D009936:Organizational Innovation; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration / Q000458:organization & administration* / Q000592:standards